These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34778040)

  • 81. Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study.
    Kim YG; Jeon JY; Kim HJ; Kim DJ; Lee KW; Moon SY; Han SJ
    J Clin Med; 2018 Dec; 8(1):. PubMed ID: 30597861
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes.
    Suissa K; Schneeweiss S; Douros A; Yin H; Patorno E; Azoulay L
    Diabetes Res Clin Pract; 2022 Oct; 192():110094. PubMed ID: 36167266
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Jung C; Park S; Kim H
    PLoS One; 2023; 18(11):e0294423. PubMed ID: 37992029
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
    Xu L; Zheng XQ; Liao XX
    Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure　- Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry.
    Yamamoto M; Seo Y; Ishizu T; Nishi I; Hamada-Harimura Y; Machino-Ohtsuka T; Sato K; Sai S; Sugano A; Obara K; Aonuma K
    Circ J; 2017 Oct; 81(11):1662-1669. PubMed ID: 28592726
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.
    Lee HF; Chan YH; Chuang C; Li PR; Yeh YH; Hsiao FC; Peng JR; See LC
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):301-310. PubMed ID: 36639127
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK; Bhatt DL; Montvida O
    Eur Heart J; 2021 May; 42(18):1728-1738. PubMed ID: 33289789
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.
    Chung CT; Lakhani I; Chou OHI; Lee TTL; Dee EC; Ng K; Wong WT; Liu T; Lee S; Zhang Q; Cheung BMY; Tse G; Zhou J
    Cancer Med; 2023 Jun; 12(11):12299-12315. PubMed ID: 37148547
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
    Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Schmedt N; Koeneman L; Déruaz-Luyet A; Paik JM; Patorno E
    Diabetologia; 2024 Jul; 67(7):1328-1342. PubMed ID: 38509341
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
    de Wit HM; Te Groen M; Rovers MM; Tack CJ
    Br J Clin Pharmacol; 2016 Jul; 82(1):301-14. PubMed ID: 26935973
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
    Fralick M; Colacci M; Thiruchelvam D; Gomes T; Redelmeier DA
    Diabetes Obes Metab; 2021 Apr; 23(4):950-960. PubMed ID: 33336894
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
    Izumi K; Nishie W; Beniko M; Shimizu H
    Front Immunol; 2019; 10():1439. PubMed ID: 31297116
    [No Abstract]   [Full Text] [Related]  

  • 95. Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients?
    Erol RS; Sen EC; Ozturk FY; Sarac Z; Kokoglu GL; Canat MM; Yildiz D; Aytekin YE; Sevgi DY; Altuntas Y
    North Clin Istanb; 2022; 9(3):207-214. PubMed ID: 36199855
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States.
    Sangha V; Lipska K; Lin Z; Inzucchi SE; McGuire DK; Krumholz HM; Khera R
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e008381. PubMed ID: 34779654
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function.
    Shi FH; Li H; Shen L; Xu L; Ge H; Gu ZC; Lin HW; Pu J
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1191-1203. PubMed ID: 34791312
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
    Zheng RJ; Wang Y; Tang JN; Duan JY; Yuan MY; Zhang JY
    J Cardiovasc Pharmacol; 2022 Feb; 79(2):e145-e152. PubMed ID: 34813574
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Initiation of SGLT2 Inhibitors and the Risk of Lower Extremity Minor and Major Amputation in Patients with Type 2 Diabetes and Peripheral Arterial Disease: A Health Claims Data Analysis.
    Rodionov RN; Peters F; Marschall U; L'Hoest H; Jarzebska N; Behrendt CA
    Eur J Vasc Endovasc Surg; 2021 Dec; 62(6):981-990. PubMed ID: 34782230
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis.
    Kawai Y; Uneda K; Yamada T; Kinguchi S; Kobayashi K; Azushima K; Kanaoka T; Toya Y; Wakui H; Tamura K
    Diabetes Res Clin Pract; 2022 Jan; 183():109146. PubMed ID: 34780865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.